Streetbeat News

Products Services

TGTX

TG Therapeutics has announced presentations for post-marketing studies of BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:38 am

ADPT

Adaptive Biotechnologies announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will be featured in several presentations at the American Society of Clinical Oncology Annual Meeting and the European Hematology Association Hybrid Congress.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:35 am

ANTE

AirNet Technology has entered into a sales and purchase agreement with an unaffiliated third party to purchase 6,218 units of Bitcoin Miner S21 for RMB177.2 million.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:32 am

SPRC

SciSparc has been granted a patent by the European Patent Office for 'Compositions And Methods Of Potentiating Antimicrobials,' adding to a similar patent previously granted by the United States Patent and Trademark Office. This strengthens the company's intellectual property portfolio and competitive position in the global pharmaceutical market.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:21 am

IVVD

Invivyd has appointed Timothy Lee as Chief Commercial Officer following the elimination of the Chief Operating Officer role to reallocate resources for the launch of PEMGARDA. The Chief Financial Officer, William Duke, Jr., will serve as Principal Executive Officer during the transition period.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:19 am

IVVD

Invivyd has disclosed a general alignment with the U.S. FDA on a repeatable and expedient emergency use authorization pathway for the prevention and treatment of symptomatic COVID-19. This pathway involves a master, registrational clinical trial protocol to streamline the evaluation of new monoclonal antibodies (mAbs). Invivyd plans to rapidly move towards a registrational clinical trial of VYD2311.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:14 am

PFE

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Pfizer's Fidanacogene Elaparvovec, a one-time gene therapy for severe Hemophilia B in adult patients.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:12 am

BA

EADSY

The IATA summit in Dubai will address challenges such as geopolitical tensions, aircraft shortages, and environmental goals. The aviation industry has returned to profitability, but faces rising costs and increased competition. Boeing's production issues and Airbus's comments highlight ongoing industry concerns.

Portfolio Pulse from Benzinga Neuro

May 31, 2024 | 11:07 am

AMD

NVDA

Jim Cramer commented on AMD, stating that while AMD under $150 would be 'terrific,' it still doesn't match Nvidia's capabilities. Despite AMD's progress in the tech industry, including securing 33% of the server CPU market and expanding partnerships, it faces challenges in competing with Nvidia, especially in the AI sector.

Portfolio Pulse from Benzinga Neuro

May 31, 2024 | 11:04 am

IONS

Ionis Pharmaceuticals announced positive results from its OASIS-HAE and OASISplus studies of the investigational medicine Donidalorsen in patients with hereditary angioedema. The studies showed significant improvements in patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:04 am